Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SITC 2021 and Car T Cellular Therapy View overview page

1:20
Differences in tumor microenvironment between female and male patients with pancreatic cancer
Dhifaf Sarhan • 12 Nov 2021
0:48
Tumor markers associated with increased survival in Phase II trial of AV-GBM-1
Daniela Bota • 12 Nov 2021
1:08
Phase II trial of AV-GBM-1 in patients with newly diagnosed glioblastoma
Daniela Bota • 12 Nov 2021
0:52
Mechanism of action of AV-GBM-1 vaccine
Daniela Bota • 12 Nov 2021
1:19
Future of dendritic cell vaccines for glioblastoma
Daniela Bota • 12 Nov 2021
0:49
Proteomic markers after injections of AV-GBM-1
Daniela Bota • 12 Nov 2021
0:26
Adverse events in the Phase II trial of AV-GBM-1
Daniela Bota • 12 Nov 2021
0:48
Is CAR-T therapy the future of cancer treatment?
Julian R. Molina • 12 Nov 2021
2:53
Assessing the predicative value of the pre-treatment TCR repertoire
Afaf Abed • 16 Nov 2021
2:13
The current status and future perspectives in immunotherapy
Howard Kaufman • 13 Nov 2021
2:41
An update on cancer vaccines
Howard Kaufman • 13 Nov 2021
2:06
Impact of hypoxia on the therapeutic potential of NK cells
Jeffrey S. Miller • 12 Nov 2021
2:55
Updates on iPSC-derived NK cells for the treatment of glioblastoma
Jeffrey S. Miller • 12 Nov 2021
1:59
Modulating the epigenome of exhausted T-cells
Debattama Sen • 13 Nov 2021
1:31
Challenges of treating solid tumors
Crystal Mackall • 12 Nov 2021
1:27
Importance of profiling the cell surface of solid tumors
Crystal Mackall • 12 Nov 2021
The content of VJOncology is intended for healthcare professionals